Search International and National Patent Collections

1. (WO2018126231) PEPTIDES DERIVED FROM KININOGEN-1 FOR PROTEIN DRUGS IN VIVO HALF-LIFE EXTENSIONS

Pub. No.:    WO/2018/126231    International Application No.:    PCT/US2017/069134
Publication Date: Fri Jul 06 01:59:59 CEST 2018 International Filing Date: Sat Dec 30 00:59:59 CET 2017
IPC: A61K 38/17
A61K 39/395
A61K 47/55
Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
DCB-USA LLC
Inventors: CHIEN, Chen-Li
CHEN, Gregory, Jiann
HSU, Chuan-Lung
CHANG, Wei-jung
WU, Chia-cheng
Title: PEPTIDES DERIVED FROM KININOGEN-1 FOR PROTEIN DRUGS IN VIVO HALF-LIFE EXTENSIONS
Abstract:
A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.